Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMARCA4 | P51532 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.35 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.32 |
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4399007 | 1.00 | SMARCA4 (0.40) | SMARCA4KDM4EMEN1KMT2AMAP1LC3B | |
| SCHEMBL1528435 | 0.87 | KDM4E (0.39) | SMARCA4KDM4EMEN1KMT2AMAP1LC3B | |
| SCHEMBL1528434 | 0.87 | KDM4E (0.39) | SMARCA4KDM4EMEN1KMT2AMAP1LC3B | |
| SCHEMBL3479747 | 0.87 | KDM4E (0.39) | SMARCA4KDM4EMEN1KMT2AMAP1LC3B | |
| SCHEMBL17376976 | 0.72 | ACHE (0.50) | SMN1; SMN2HIF1A | |
| SCHEMBL17376975 | 0.72 | ACHE (0.50) | SMN1; SMN2HIF1A | |
| SCHEMBL17376974 | 0.72 | ACHE (0.50) | SMN1; SMN2HIF1A | |
| SCHEMBL1528523 | 0.72 | CYP2B6 (0.36) | MEN1KMT2AMAPTSMN1; SMN2CYP2B6 | |
| SCHEMBL3733266 | 0.71 | ALDH1A1 (0.49) | MEN1KMT2AALDH1A1MAPTHTT | |
| SCHEMBL3733271 | 0.71 | ALDH1A1 (0.49) | MEN1KMT2AALDH1A1MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1554256-B1 | PIPERIDINO PYRIMIDINE DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OF DIABETES | MERCK & CO INC (US) | 2009-12-09 | — | — | EP | disclosed |
| US-7208498-B2 | Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes | MERCK & CO., INC. (US) | 2007-04-24 | — | — | US | disclosed |
| US-20060040963-A1 | Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes | MERCK SHARP & DOHME LLC | 2006-02-23 | — | — | US | disclosed |
| US-6653302-B2 | Benign prostatic hyperplasia | PFIZER INC. | 2003-11-25 | — | — | US | disclosed |
| US-20030130259-A1 | Quinoline and quinazoline compounds useful in therapy | FOX DAVID NATHAN ABRAHAM (GB) | 2003-07-10 | — | — | US | disclosed |
| EP-0968208-B1 | QUINOLINE AND QUINAZOLINE COMPOUNDS USEFUL IN THERAPY, PARTICULARLY IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | PFIZER LTD (GB) | 2003-06-04 | — | — | EP | disclosed |
| US-6521629-B2 | 2-amine substituted quinoline or quinozoline derivatives useful for treating benign prostatic hyperplasia | PFIZER INC. | 2003-02-18 | — | — | US | disclosed |
| US-20020040028-A1 | Quinoline and quinazoline compounds useful in therapy | FOX DAVID NATHAN ABRAHAM (GB) | 2002-04-04 | — | — | US | disclosed |
| US-6365599-B1 | FOR THERAPY OF BENIGN PROSTATIC HYPERPLASIA | PFIZER, INC. | 2002-04-02 | — | — | US | disclosed |
| US-6169093-B1 | FOR TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | PFIZER INC. | 2001-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130259-A1 | Quinoline and quinazoline compounds useful in therapy | NQO2, RFT1, LPXN | SMARCA4 3062/4885KDM4E 2897/4885MEN1 118/4885 |
| US-20020040028-A1 | Quinoline and quinazoline compounds useful in therapy | BPHL, LPXN, NQO2 | SMARCA4 2994/4885KDM4E 2920/4885MEN1 92/4885 |
| US-20060040963-A1 | Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes | DPP4, DPP3, DPP7 | SMARCA4 3696/4885KDM4E 578/4885MEN1 4690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.